TRANSFORMED FOLLICULAR LYMPHOMA
Clinical trials for TRANSFORMED FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The …
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New Dual-Target CAR-T therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The goal is to find the saf…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New combo may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether giving two drugs (loncastuximab tesirine and rituximab) before standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has come back or not responded to treatment. About 29 participants will receive this bridging therap…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New combo therapy aims to stop aggressive lymphoma relapse
Disease control Recruiting nowThis study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Can a simple training improve tough cancer conversations?
Knowledge-focused Recruiting nowThis study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. About 48 people (doctors and patients) will take part to…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:56 UTC